Accrued Liabilities, Current of Evelo Biosciences, Inc. from 31 Dec 2017 to 30 Sep 2023

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Evelo Biosciences, Inc. quarterly Accrued Liabilities, Current in USD history and change rate from 31 Dec 2017 to 30 Sep 2023.
  • Evelo Biosciences, Inc. Accrued Liabilities, Current for the quarter ending 30 Sep 2023 was $4,550,000, a 64% decline year-over-year.
Source SEC data
View on sec.gov
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Change (%)

Evelo Biosciences, Inc. Quarterly Accrued Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2023 $4,550,000 -$7,928,000 -64% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $5,151,000 -$5,272,000 -51% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $9,506,000 -$370,000 -3.7% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $7,945,000 -$5,123,000 -39% 31 Dec 2022 10-Q 09 Nov 2023 2023 Q3
Q3 2022 $12,478,000 -$3,163,000 -20% 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $10,423,000 -$2,645,000 -20% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $9,876,000 -$3,192,000 -24% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $13,068,000 -$3,186,000 -20% 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $15,641,000 +$6,818,000 +77% 30 Sep 2021 10-Q/A 29 Oct 2021 2021 Q3
Q2 2021 $13,068,000 +$5,082,000 +64% 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $13,068,000 +$4,029,000 +45% 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $16,254,000 +$7,496,000 +86% 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $8,823,000 +$904,000 +11% 30 Sep 2020 10-Q 30 Oct 2020 2020 Q3
Q2 2020 $7,986,000 +$1,072,000 +16% 30 Jun 2020 10-Q 31 Jul 2020 2020 Q2
Q1 2020 $9,039,000 +$3,802,000 +73% 31 Mar 2020 10-Q 11 May 2020 2020 Q1
Q4 2019 $8,758,000 +$3,793,000 +76% 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $7,919,000 +$2,358,000 +42% 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 $6,914,000 +$2,230,000 +48% 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $5,237,000 +$2,287,000 +78% 31 Mar 2019 10-Q 03 May 2019 2019 Q1
Q4 2018 $4,965,000 +$2,766,000 +126% 31 Dec 2018 10-K 14 Feb 2020 2019 FY
Q3 2018 $5,561,000 30 Sep 2018 10-Q 02 Nov 2018 2018 Q3
Q2 2018 $4,684,000 30 Jun 2018 10-Q 02 Aug 2018 2018 Q2
Q1 2018 $2,950,000 31 Mar 2018 10-Q 31 May 2018 2018 Q1
Q4 2017 $2,199,000 31 Dec 2017 10-K 15 Feb 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.